XML 40 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue- Gilead Science Inc (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Oct. 14, 2022
Jun. 30, 2024
Oct. 31, 2022
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Sep. 30, 2023
Collaboration And Other Agreements [Line Items]              
Revenues       $ 13,192 $ 9,104    
Deferred revenue, current       15,620   $ 16,319  
Deferred revenue, net of current portion       55,938   55,503  
Gilead | 2022 Gilead Collaboration And License Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment     $ 60,000        
Revenues       0 300    
Deferred revenue       57,100   56,800  
Deferred revenue, current       1,200   1,300  
Deferred revenue, net of current portion       55,900   55,500  
Potential target nomination, option fees and milestone payments $ 1,700,000            
Gilead | Gilead First Research Program              
Collaboration And Other Agreements [Line Items]              
Revenues   $ 3,300   5,400 $ 700    
Deferred revenue       5,600   11,000  
Deferred revenue, current       $ 5,600   $ 11,000  
Revenue, remaining performance obligation, amount             $ 15,700
Potential option fees             $ 10,000